Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$82,323.00-1.41%ETH$2,533.48-1.48%GOLD$4,146.30+0.14%OIL$92.57+4.86%
Smart Investors Daily
SID Premium
KR

NASDAQ · KRMD

KORU Medical Systems, Inc.

Healthcare · Medical - Instruments & Supplies

$2.98

Down-$0.02 (-0.67%)

Updated Oct 8, 2026, 12:50 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
271.03M
P/E ratio
-72.99
Dividend yield
0.00%
52-week range
$2.86 – $4.72
Volume
111.05K
Avg. volume
128.93K

Price performance · KRMD

KRMD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

KRMD closed at $2.98 after 21 trading sessions, down 5.40% for the selected period.

Last close
$2.98
Period change
-5.40%
Period low
$2.93
Period high
$3.31
Daily close
View OHLC price history
KRMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$2.98$3.045$2.96$2.98111.05K
Oct 6, 2026$3.02$3.02$2.95$3.00129.56K
Oct 5, 2026$2.99$3.025$2.91$3.01206.4K
Oct 2, 2026$3.11$3.255$2.94$2.96274.89K
Oct 1, 2026$2.94$3.04$2.86$3.02280.88K
Sep 30, 2026$3.02$3.02$2.90$2.93268.16K
Sep 29, 2026$3.04$3.05$2.98$3.005243.82K
Sep 28, 2026$3.21$3.245$3.015$3.06226.93K
Sep 25, 2026$3.27$3.30$2.99$3.21368.55K
Sep 24, 2026$3.26$3.29$3.18$3.27357.03K
Sep 23, 2026$3.31$3.39$3.20$3.27465.62K
Sep 22, 2026$3.25$3.325$3.20$3.31611.52K
Sep 21, 2026$3.23$3.27$3.20$3.23265.26K
Sep 18, 2026$3.18$3.245$3.062$3.23677.66K
Sep 17, 2026$3.23$3.23$3.15$3.22174.87K
Sep 16, 2026$3.16$3.22$3.13$3.20316.33K
Sep 15, 2026$3.14$3.17$3.09$3.16183.83K
Sep 14, 2026$3.16$3.18$3.1223$3.14163.32K
Sep 11, 2026$3.18$3.19$3.14$3.16129.47K
Sep 10, 2026$3.23$3.24$3.1199$3.15160.23K
Sep 9, 2026$3.21$3.27$3.12$3.15180.56K

Latest KRMD news

The latest Smart Investors Daily articles mentioning KRMD.

Stock researchCompany · Overview

KRMD research

Overview

Company profile and research snapshot.

Company profile

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.25
Implied upside
—
Analysts
11
KRMD recent ratings
DateFirmRatingTarget
Mar 13, 2026B. Riley SecuritiesBuy—
Mar 13, 2026Canaccord GenuityBuy—
Dec 22, 2025Lake StreetBuy—
Dec 17, 2025Canaccord GenuityBuy—
May 8, 2025Piper SandlerNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 26, 2026

KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

MAHWAH, N.J., February 26, 2026--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that

Yahoo · Feb 10, 2026

February 2026's Noteworthy Stocks Estimated Below Intrinsic Value

As February 2026 begins, U.S. stock markets have shown a strong start with major indices like the Dow Jones and S&P 500 ending sharply higher, reflecting investor optimism despite ongoing geopolitical and economic uncertainties. In this environment of fluctuating market dynamics and evolving trade agreements, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on discrepancies between market price and intrinsic value.

Yahoo · Feb 10, 2026

3 Stocks Estimated To Be Up To 49.8% Below Intrinsic Value

As the United States stock market begins February on a high note with major indexes like the Dow Jones and S&P 500 showing significant gains, investors are keenly observing opportunities amidst fluctuating economic indicators and geopolitical developments. In this environment, identifying undervalued stocks becomes crucial as they may offer potential for growth when trading below their intrinsic value.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By